IONIS PHARMACEUTICALS INC 4

EVP & Chief Scientific Officer C. Frank Bennett sold a total of 20,536 shares of Ionis Pharmaceuticals common stock (including 15,000 via his trust after an RSU-related transfer) on July 7, 2026 under a Rule 10b5-1 plan, and now holds 75,018 shares directly.

On July 7, 2026, C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, Inc., executed several related transactions in Ionis common stock. He sold 5,536 directly held shares at a weighted average price of $83.579 per share under a pre-arranged Rule 10b5-1 trading plan, for proceeds of roughly $462,000, reducing his direct holdings to 75,018 shares. On the same day, 15,000 shares previously received from a vested restricted stock unit were transferred from his direct ownership to indirect ownership in the Clarence Frank Bennett TTEE Bennett Living Trust dated March 12, 2008, of which he and his spouse are co-trustees, and then those 15,000 indirectly held shares were sold at a weighted average price of $85.462 per share, for proceeds of about $1.28 million, leaving zero shares held indirectly by the trust post-sale. The RSU underlying the 15,000 shares had vested earlier on January 15, 2026 and was settled in shares, and following all of these transactions Bennett retained 75,018 directly held shares, valued at approximately $6.3 million based on the disclosed sale price context.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

fda

Accession

0000874015-26-000239

Alert Tier

7